ASA Sends Formal Letter to FDA Supporting Development of Appropriately Sized Vials

ASA continues to strongly support the availability of vial sizes appropriate for the labeled use and dosing of the product.  Fresenius Kabi, for example, recently released Diprivan® in 10 mL single patient  infusion vials.  In a June 12, 2014 formal comment letter to the Food and Drug Administration (FDA), ASA emphasized that critical anesthesia drugs are still in shortage, and the availability of appropriately sized vials will help limit waste of drugs in shortage. 

ASA looks forward to continue working with the FDA and manufacturers on efforts to prevent and mitigate drug shortages and to identify opportunities for the creation of appropriately sized vials and prefilled syringes.

Learn more about ASA’s advocacy on drug shortages.